ArticleBlood2012
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 89 citations in OpenAlex.
- Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.Haematologica · 2019Trial
- High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.Bone marrow transplantation · 2015Trial
- Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.Bone marrow transplantation · 2014Trial
- Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.Bone marrow transplantation · 2014Trial
- The pre-ASCT serum albumin and pre-ASCT dFLC are prognostic markers in renal light chain amyloidosis patients treated with autologous stem cell transplantation.Bone marrow transplantation · 2025Article
- Incidental Extracardiac Findings of Technetium-99m Pyrophosphate Scintigraphy: A Pictorial Review.Cureus · 2024Review
- Molecular Mechanisms of Cardiac Amyloidosis.International journal of molecular sciences · 2021Review
- Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.ESC heart failure · 2021Review
- Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment.Circulation. Cardiovascular imaging · 2021Review
- Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).Clinical research in cardiology : official journal of the German Cardiac Society · 2021Review
- Narrative review of pharmacotherapy for transthyretin cardiac amyloid.Annals of translational medicine · 2021Review
- Incidentally detected cardiac amyloidosis onRadiology case reports · 2020Article
- Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis.JACC. CardioOncology · 2020Article
- Cardiac amyloidosis presenting with recurrent ischaemic strokes.BMJ case reports · 2020Article
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Nuclear imaging of cardiac amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers.Bone marrow transplantation · 2018Article
- Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.American health & drug benefits · 2018Article
- Advances in Treatment of Cardiac Amyloid.Current treatment options in cardiovascular medicine · 2018Review
- Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.Trends in cardiovascular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement. We studied 187 patients with cardiac involvement with AL who underwent HDM between 1996 and 2008. The median age was 57 years and the median time from diagnosis to HDM was 3.6 months. Half of the patients received reduced-dose melphalan (100-160 mg/m(2)). The median overall survival (OS) was 66 months, 54 months from diagnosis and HDM, respectively, and 91 patients (49%) were alive at the last follow-up 52 months (median) from HDM. Thirty patients (16%) died within 100 days of transplantation; only low serum albumin predicted early deaths. Overall, hematologic response (HR) and cardiac responses were seen in 66% and 41% of patients, respectively. The median OS for patients with and without HR was not reached and 22 months, respectively (P < .01); and for those with any decrease and no decrease in N-terminal-pro-brain natriuretic peptide was not reached and 26 months, respectively (P < .01). In multivariate analysis of baseline factors, only reduced-dose melphalan predicted shorter OS. HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ response is associated with improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.